팽윤성 코어를 포함하는 TYK2 억제제를 위한 투여 형태

팽윤성 코어 투여 형태는 무정형 6-(시클로프로판아미도)-4-((2-메톡시-3-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)아미노)-N-(메틸-d3)피리다진-3-카르복스아미드의 분산물을 포함한다. A swellable core dosage form comprises a dispersion of amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide....

Full description

Saved in:
Bibliographic Details
Main Authors KOEHLER KING DORY, SATHER CRAIG ALLEN, BADAWY SHERIF IBRAHIM FARAG, KYBURZ KYLE, KESTUR UMESH
Format Patent
LanguageKorean
Published 19.05.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:팽윤성 코어 투여 형태는 무정형 6-(시클로프로판아미도)-4-((2-메톡시-3-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)아미노)-N-(메틸-d3)피리다진-3-카르복스아미드의 분산물을 포함한다. A swellable core dosage form comprises a dispersion of amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.
Bibliography:Application Number: KR20237012594